Personalis and Tempus Collaborate to Advance Cancer Testing
Personalis and Tempus Labs announced a collaboration to co-commercialize a whole genome-based liquid biopsy LDT for MRD and cancer detection.
Read MorePosted by Andy Lundin | Dec 4, 2023 | Cancer, Company News |
Personalis and Tempus Labs announced a collaboration to co-commercialize a whole genome-based liquid biopsy LDT for MRD and cancer detection.
Read MorePosted by Andy Lundin | Nov 29, 2023 | Digital Pathology, Slides |
Pathology labs that are slow to adopt slide digitization technologies may be working with poor quality and inconsistent images.
Read MorePosted by Andy Lundin | Nov 28, 2023 | Allergy & Autoimmune |
Quest and Scipher Medicine will collaborate to expand access to diagnostic services advancing precision medicine for rheumatoid arthritis.
Read MorePosted by Andy Lundin | Nov 27, 2023 | Dementias & Alzheimer’s |
BrainSpec was awarded FDA clearance to begin using its MRS platform for non-invasive measurement of brain chemistry.
Read MorePosted by Chris Wolski | Nov 22, 2023 | Disease States |
Metabolic dysfunction-associated steatotic liver disease is estimated to affect about 32.4% of the world’s population.
Read More